Dystrophic epidermolysis bullosa pruriginosa
Learn about Dystrophic epidermolysis bullosa pruriginosa, its reported features, relevant specialists, and questions to discuss at a medical consultation.
Also known as: DEB pruriginosa; DEB-Pr; Pruriginous dystrophic epidermolysis bullosa
The sources compiled here do not cover: diagnosis, treatment, prevention, prognosis. Ask the treating doctor about these.
What it is
From: Orphanet
A rare dystrophic epidermolysis bullosa (DEB) characterized by generalized or localized skin lesions associated with severe, if not intractable, pruritus.
Reported clinical features and what the terms mean
The following findings are associated with this condition in Orphanet. They are not a checklist for diagnosing yourself, and they do not all occur in every affected person. Some are examination, imaging or laboratory findings that cannot be recognised at home.
The frequency labels describe how often a finding was reported among people with the condition in the source. They do not give the chance that a person with that symptom has the condition. Definitions below reproduce HPO terminology; they explain the term, not the likely severity in an individual.
- Abnormal blistering of the skin · Very frequent (99-80%)
- The presence of one or more bullae on the skin, defined as fluid-filled blisters more than 5 mm in diameter with thin walls.
- Pruritus · Very frequent (99-80%)
- Pruritus is an itch or a sensation that makes a person want to scratch. This term refers to an abnormally increased disposition to experience pruritus.
- Abnormality of the elbow · Frequent (79-30%)
- An anomaly of the joint that connects the upper and the lower arm.
- Abnormality of the wrist · Frequent (79-30%)
- Abnormality of the wrist, the structure connecting the hand and the forearm.
- Lichenification · Frequent (79-30%)
- Thickening and hardening of the epidermis seen with exaggeration of normal skin lines.
- Nail dystrophy · Frequent (79-30%)
- Onychodystrophy (nail dystrophy) refers to nail changes apart from changes of the color (nail dyschromia) and involves partial or complete disruption of the various keratinous layers of the nail plate.
- Pretibial blistering · Frequent (79-30%)
- A type of blistering that affects the skin of the tibial region.
- Skin plaque · Frequent (79-30%)
- A plaque is a solid, raised, plateau-like (flat-topped) lesion greater than 1 cm in diameter.
- Abnormal toenail morphology · Occasional (29-5%)
- An anomaly of the toenail.
- Abnormality of head or neck · Occasional (29-5%)
- An abnormality of head and neck.
- Abnormality of the forearm · Occasional (29-5%)
- An abnormality of the lower arm.
- Atrophic scars · Occasional (29-5%)
- Scars that form a depression compared to the level of the surrounding skin because of damage to the collagen, fat or other tissues below the skin.
- Dermal atrophy · Occasional (29-5%)
- Partial or complete wasting (atrophy) of the skin.
- Hyperkeratosis · Occasional (29-5%)
- Hyperkeratosis is a histopathological term defining a thickened stratum corneum and may be present in many different skin conditions, with many possible overlaps. Hyperkeratosis refers to the increased thickness of the stratum corneum, the outer layer of the skin. Hyperkeratosis is subclassified as orthokeratotic or parakeratotic. Orthokeratotic hyperkeratosis refers to the thickening of the keratin layer with preserved keratinocyte maturation, while parakeratotic hyperkeratosis shows retained nuclei as a sign of delayed maturation of keratinocytes.
Other findings in the same source
From: Orphanet
Additional reported features include Junctional split (Occasional (29-5%)); Milia (Occasional (29-5%)); Papule (Occasional (29-5%)); Scarring (Occasional (29-5%)); Subcutaneous nodule (Occasional (29-5%)); Increased circulating IgE concentration (Very rare (<4-1%)). This is a selected summary, not a complete description of the condition.
When it may begin
From: Orphanet
Childhood
Inheritance in the source
From: Orphanet
Autosomal dominant; Autosomal recessive
Frequency and the population described
From: Orphanet
Reported family(ies): 100.0; Worldwide. This is a published case count, not prevalence. Point prevalence: Unknown; Worldwide; Class only.
Which doctor should you see?
The suggested department for discussing Dystrophic epidermolysis bullosa pruriginosa is Dermatology, with a dermatologist as the relevant type of clinician. Dermatologist; paediatric services for children as appropriate.
Additional services that may be relevant, depending on the findings, include: Clinical Genetics.
This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.
How to prepare for an assessment
Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.
Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.
- Which features of the skin, hair or nails distinguish the possibilities?
- Would photographs over time help document the changes?
- What should be expected from treatment, and how will irritation or other adverse effects be managed?
Treatment discussions and follow-up
The material gathered for this draft does not provide a complete condition-specific treatment pathway for Dystrophic epidermolysis bullosa pruriginosa. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.
Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.
The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.
When to seek emergency help
Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.
This condition is usually assessed by a dermatologist. Every profile shows the doctor’s registration and what has been checked.
Sources
- Orphanet — Dystrophic epidermolysis bullosa pruriginosa — Orphadata Science, CC BY 4.0
- Human Phenotype Ontology Consortium — terminology definitions — HPO licence; definitions reproduced without alteration
- Government of India — Emergency Response Support System — Official reference for India emergency number
Source: MedlinePlus, National Library of Medicine. Orphadata Science: Free access data from Orphanet. © INSERM 1999; July 2026 data, CC BY 4.0. This product uses the Human Phenotype Ontology (hp/releases/2026-09-01). Only sources listed for this article apply. Source material has been selected and arranged; HPO definitions are reproduced without alteration. No source organisation endorses this compilation. Köhler S et al. The Human Phenotype Ontology project: linking molecular biology and disease through phenotype data. Nucleic Acids Research 2014;42(D1):D966–D974. doi:10.1093/nar/gkt1026.
General information, not advice about your situation. Errors can be reported through the corrections process. Reference TDI-C-0800.